{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"podcast":2,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06679101\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DREAMM-10","nct_id":"NCT06679101","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dreamm-10-nct06679101. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DREAMM-10","arms":[{"description":"Belantamab mafodotin, lenalidomide, and dexamethasone will be administered.\n\nTreatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.","label":"Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone","type":"EXPERIMENTAL"},{"description":"Daratumumab, lenalidomide, and dexamethasone will be administered.\n\nTreatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.","label":"Arm B: Daratumumab + Lenalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-04-28","type":"ESTIMATED"},"conditions":["Multiple Myeloma","Newly Diagnosed Multiple Myeloma"],"enrollment":{"count":520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Belantamab mafodotin","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"}],"last_update":"2026-04-22","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-04-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS","timeFrame":"Up to approximately 7 years"},{"measure":"Number of Participants Achieving MRD Negative Status","timeFrame":"Up to approximately 7 years"}],"references":[],"start_date":{"date":"2024-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","url":"https://clinicaltrials.gov/study/NCT06679101"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dreamm-10-nct06679101"}